These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28468516)

  • 1. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
    Emambux S; Italiano A
    Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
    Seetharam M; Kolla KR; Chawla SP
    Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
    O'Shaughnessy J; Kaklamani V; Kalinsky K
    Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin: rediscovering tubulin as an anticancer target.
    Jimeno A
    Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate (Halaven) for breast cancer.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
    Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
    Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
    Dybdal-Hargreaves NF; Risinger AL; Mooberry SL
    Clin Cancer Res; 2015 Jun; 21(11):2445-52. PubMed ID: 25838395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin mesylate in breast cancer.
    Verdaguer H; Morilla I; Urruticoechea A
    Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
    Polastro L; Aftimos PG; Awada A
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
    Cortes J; Montero AJ; Glück S
    Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.